Jun 2026 (Q2 FY26) — Aug 5, 2026
Cytek Biosciences Q2 FY26 — Strong US & China Growth, New Product Launches
Read the full callCytek Biosciences (CTKB) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Cytek Biosciences earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 48.1 | +5.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -23.7 | −0.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -12.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$5.41 +0.19% · +$0.01
Performance +34.9% 1Y
1Y: $4.01 on 14 Oct 2025 → $5.41. High $6.09 (5 Oct 2026), low $3.36 (14 May 2026).
- Previous close
- $5.4
- 52-week range
- $3.36 – $6.09
- One year
- +33.25%
Overview
- Symbol
- CTKB
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Cytek Biosciences earnings calls (CTKB)
Financials
What the filings say
Net profit, year on year: −118% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 52 | 57 | 41 | 46 | 52 | 62 | 44 | 48 |
| Operating profit | -4 | 3 | -15 | -11 | -9 | -6 | -18 | -11 |
| Operating margin | −8.3% | 5.2% | −36.1% | −23.3% | −17.6% | −9.0% | −41.8% | −23.7% |
| Other income | 4 | 7 | 4 | 4 | 1 | 2 | 1 | -0 |
| Interest | 0 | -6 | 0 | 0 | 0 | -1 | 0 | 0 |
| Profit before tax | 0 | 10 | -11 | -7 | -8 | -4 | — | — |
| Tax rate | −499.4% | 6.6% | −1.2% | 17.6% | 29.5% | −993.4% | — | — |
| Net profit | — | — | -11 | -6 | — | — | -19 | -12 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -23 | -20 | -17 | -29 | -35 | -102 |
| Total liabilities | 42 | 58 | 94 | 101 | 104 | 120 |
| Fixed assets | 2 | 6 | 14 | 18 | 18 | 18 |
| Total assets | 220 | 463 | 519 | 494 | 500 | 462 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | 15 | 5 | -12 | 5 | 25 | -5 |
| Cash from investing | -2 | -21 | -56 | -94 | -83 | 10 |
| Cash from financing | 123 | 214 | 6 | -42 | -16 | -13 |
| Net cash flow | 136 | 198 | -65 | -132 | -69 | -8 |
| Capital expenditure | -2 | -4 | -10 | -5 | -4 | -4 |
| Free cash flow | 14 | 0 | -22 | 1 | 22 | -9 |
Insider filings
143 filings between Nov 18, 2025 and Aug 18, 2026.
Open market
decisions to buy or sellNobody bought or sold CTKB on the open market in this window. The filings below are 77 option exercises, 64 tax withholdings and 2 gifts.
Compensation
not trading decisions- 77
- Option exercise — converted options into shares
- 64
- Tax withheld — shares kept back by the company to cover tax
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 18, 2026 | Yan Ming CHIEF TECHNOLOGY OFFICER | Tax withheld | 3,463 | $16.2K |
| Aug 18, 2026 | Yan Ming CHIEF TECHNOLOGY OFFICER | Option exercise | 5,525 | — |
| Aug 18, 2026 | McCombe William D. Chief Financial Officer | Tax withheld | 2,111 | $9.9K |
| Aug 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Tax withheld | 7,062 | $33.0K |
| Aug 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Tax withheld | 5,382 | $25.1K |
| Aug 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Tax withheld | 2,869 | $13.4K |
| Aug 18, 2026 | Holder Michael Director | Option exercise | 2,181 | — |
| Aug 18, 2026 | McCombe William D. Chief Financial Officer | Option exercise | 13,051 | — |
| Aug 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Tax withheld | 20,956 | $97.9K |
| Aug 18, 2026 | Yan Ming CHIEF TECHNOLOGY OFFICER | Tax withheld | 1,501 | $7.0K |
| Aug 18, 2026 | Yan Ming CHIEF TECHNOLOGY OFFICER | Option exercise | 6,162 | — |
| Aug 18, 2026 | McCombe William D. Chief Financial Officer | Option exercise | 6,320 | — |
| Aug 18, 2026 | Yan Ming CHIEF TECHNOLOGY OFFICER | Tax withheld | 1,346 | $6.3K |
| Aug 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Option exercise | 22,100 | — |
| Aug 18, 2026 | Yan Ming CHIEF TECHNOLOGY OFFICER | Option exercise | 7,363 | — |
| Aug 18, 2026 | McCombe William D. Chief Financial Officer | Tax withheld | 5,401 | $25.2K |
| Aug 18, 2026 | McCombe William D. Chief Financial Officer | Option exercise | 16,049 | — |
| Aug 18, 2026 | Chin Richard Director | Option exercise | 6,107 | — |
| Aug 18, 2026 | Yan Ming CHIEF TECHNOLOGY OFFICER | Tax withheld | 1,778 | $8.3K |
| Aug 18, 2026 | MUIR GLENN P Director | Option exercise | 3,086 | — |
| Aug 18, 2026 | McCombe William D. Chief Financial Officer | Tax withheld | 4,392 | $20.5K |
| Aug 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Option exercise | 57,212 | — |
| Aug 18, 2026 | Yan Ming CHIEF TECHNOLOGY OFFICER | Option exercise | 14,220 | — |
| Aug 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Option exercise | 29,002 | — |
| Aug 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Option exercise | 11,781 | — |
| Jun 12, 2026 | Yan Ming CHIEF TECHNOLOGY OFFICER | Gift | 135,892 | $0 |
| Jun 10, 2026 | Ball Jack Director | Option exercise | 43,973 | — |
| Jun 10, 2026 | Holder Michael Director | Option exercise | 43,973 | — |
| Jun 10, 2026 | NEFF DEBORAH J Director | Option exercise | 43,973 | — |
| Jun 10, 2026 | Imper Vera Director | Option exercise | 43,973 | — |
| May 18, 2026 | Yan Ming CHIEF TECHNOLOGY OFFICER | Tax withheld | 1,224 | $4.3K |
| May 18, 2026 | Yan Ming CHIEF TECHNOLOGY OFFICER | Option exercise | 4,908 | — |
| May 18, 2026 | Barnett Valerie CHIEF LEGAL OFFICER | Tax withheld | 2,602 | $9.2K |
| May 18, 2026 | Barnett Valerie CHIEF LEGAL OFFICER | Tax withheld | 1,850 | $6.6K |
| May 18, 2026 | Barnett Valerie CHIEF LEGAL OFFICER | Option exercise | 5,156 | — |
| May 18, 2026 | Barnett Valerie CHIEF LEGAL OFFICER | Tax withheld | 881 | $3.1K |
| May 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Tax withheld | 15,009 | $53.3K |
| May 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Option exercise | 38,141 | — |
| May 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Tax withheld | 5,032 | $17.9K |
| May 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Option exercise | 19,334 | — |
| May 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Tax withheld | 3,588 | $12.7K |
| May 18, 2026 | Barnett Valerie CHIEF LEGAL OFFICER | Option exercise | 2,454 | — |
| May 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Option exercise | 14,733 | — |
| May 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Tax withheld | 1,913 | $6.8K |
| May 18, 2026 | Jiang Wenbin PRESIDENT AND CEO | Option exercise | 7,854 | — |
| May 18, 2026 | Barnett Valerie CHIEF LEGAL OFFICER | Option exercise | 7,250 | — |
| May 18, 2026 | Holder Michael Director | Option exercise | 1,454 | — |
| May 18, 2026 | Chin Richard Director | Option exercise | 6,107 | — |
| May 18, 2026 | Barnett Valerie CHIEF LEGAL OFFICER | Tax withheld | 3,386 | $12.0K |
| May 18, 2026 | Barnett Valerie CHIEF LEGAL OFFICER | Option exercise | 9,435 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Cytek Biosciences, Inc.
Free account. Everything above stays public.
Write why you follow Cytek Biosciences, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading